These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20185312)

  • 41. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
    Dautzenberg FM; Py-Lang G; Higelin J; Fischer C; Wright MB; Huber G
    J Pharmacol Exp Ther; 2001 Jan; 296(1):113-20. PubMed ID: 11123370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and structure-affinity relationships of 4-(5-Aryl-1,2,3,6-tetrahydropyridino)pyrimidine derivatives as corticotropin-releasing factor(1) receptor antagonists.
    Kumagai T; Okubo T; Kataoka-Okubo H; Chaki S; Okuyama S; Nakazato A
    Bioorg Med Chem; 2001 May; 9(5):1349-55. PubMed ID: 11377192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists.
    Takeda K; Terauchi T; Hashizume M; Shikata K; Taguchi R; Murata-Tai K; Fujisawa M; Takahashi Y; Shin K; Ino M; Shibata H; Yonaga M
    Bioorg Med Chem; 2012 Nov; 20(22):6559-78. PubMed ID: 23062820
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G
    J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines.
    Gillespie RJ; Bamford SJ; Botting R; Comer M; Denny S; Gaur S; Griffin M; Jordan AM; Knight AR; Lerpiniere J; Leonardi S; Lightowler S; McAteer S; Merrett A; Misra A; Padfield A; Reece M; Saadi M; Selwood DL; Stratton GC; Surry D; Todd R; Tong X; Ruston V; Upton R; Weiss SM
    J Med Chem; 2009 Jan; 52(1):33-47. PubMed ID: 19072055
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
    Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
    J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
    Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
    J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.
    Cosimelli B; Greco G; Ehlardo M; Novellino E; Da Settimo F; Taliani S; La Motta C; Bellandi M; Tuccinardi T; Martinelli A; Ciampi O; Trincavelli ML; Martini C
    J Med Chem; 2008 Mar; 51(6):1764-70. PubMed ID: 18269230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.
    Baraldi PG; Cacciari B; Spalluto G; Bergonzoni M; Dionisotti S; Ongini E; Varani K; Borea PA
    J Med Chem; 1998 Jun; 41(12):2126-33. PubMed ID: 9622554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
    Hartz RA; Ahuja VT; Rafalski M; Schmitz WD; Brenner AB; Denhart DJ; Ditta JL; Deskus JA; Yue EW; Arvanitis AG; Lelas S; Li YW; Molski TF; Wong H; Grace JE; Lentz KA; Li J; Lodge NJ; Zaczek R; Combs AP; Olson RE; Mattson RJ; Bronson JJ; Macor JE
    J Med Chem; 2009 Jul; 52(14):4161-72. PubMed ID: 19552436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides.
    Mazur AW; Wang F; Tscheiner M; Donnelly E; Isfort RJ
    J Med Chem; 2004 Jun; 47(13):3450-4. PubMed ID: 15189041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. N-phenylphenylglycines as novel corticotropin releasing factor receptor antagonists.
    Molteni V; Penzotti J; Wilson DM; Termin AP; Mao L; Crane CM; Hassman F; Wang T; Wong H; Miller KJ; Grossman S; Grootenhuis PD
    J Med Chem; 2004 May; 47(10):2426-9. PubMed ID: 15115386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
    Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP
    J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 2-Aryl-3,6-dialkyl-5-dialkylaminopyrimidin-4-ones as novel crf-1 receptor antagonists.
    Hodgetts KJ; Yoon T; Huang J; Gulianello M; Kieltyka A; Primus R; Brodbeck R; De Lombaert S; Doller D
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2497-500. PubMed ID: 12852951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.
    Di Fabio R; Arban R; Bernasconi G; Braggio S; Blaney FE; Capelli AM; Castiglioni E; Donati D; Fazzolari E; Ratti E; Feriani A; Contini S; Gentile G; Ghirlanda D; Sabbatini FM; Andreotti D; Spada S; Marchioro C; Worby A; St-Denis Y
    J Med Chem; 2008 Nov; 51(22):7273-86. PubMed ID: 18975927
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
    Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE
    J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
    Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP
    J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat.
    Harro J; Tõnissaar M; Eller M
    Neuropeptides; 2001 Apr; 35(2):100-9. PubMed ID: 11384205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and pharmacological screening of derivatives of isoxazolo[4,5-d]pyrimidine.
    Wagner E; Al-Kadasi K; Zimecki M; Sawka-Dobrowolska W
    Eur J Med Chem; 2008 Nov; 43(11):2498-504. PubMed ID: 18358570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis of cycloalkane-annelated 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines and their evaluation as 5-HT6 receptor antagonists.
    Ivachtchenko AV; Dmitriev DE; Golovina ES; Dubrovskaya ES; Kadieva MG; Koryakova AG; Kysil VM; Mitkin OD; Tkachenko SE; Okun IM; Vorobiov AA
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2133-6. PubMed ID: 20207539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.